Ishita Drugs & Industries Ltd — Results, 12-08-2025: Result

Ishita Drugs' board has approved the financial results for the quarter ended June 30, 2025. The Board also approved the reappointment of Mr. Arvind Vilasrao Sapkal as an Independent Director for five more years, pending shareholder approval. Additionally, an amendment to the 32nd Annual General Meeting notice was approved. The board further decided to explore new business opportunities that align with the company's Memorandum of Association. These decisions focus on enhancing corporate governance and opening avenues for future business expansion.